Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

ATLANTA - Each year, millions of American men get a blood test known as a PSA, or prostate-specific antigen, test as part of their yearly checkup. PSA is a protein produced by the prostate gland. If a ...

P rostate-specific antigen (PSA) is a protein made by the prostate gland. A high PSA level could be a sign of an enlarged prostate, inflammation called prostatitis, or prostate cancer. The PSA test ...

WASHINGTON (AP) - A rising PSA level isn't such a good predictor of prostate cancer after all and can lead to many unnecessary biopsies, says a large new study. Most men over 50 get PSA blood tests, ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Subscribe to our newsletter for the latest sci-tech ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...

Credit: Getty Images Findings have implications for counseling patients treated with radiation therapy plus ADT in routine clinical practice. PSA levels of 0.1 ng/mL or higher within 6 months of ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...